Oral propranolol for infantile hemangiomas beyond the proliferative phase

Kagami, Shinji; Katori, Tatsuo

doi:10.1111/1346-8138.14581

Cited by 4 publications

(2 citation statements)

References 13 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With Octanol–Water Partition Coefficient (Kow) of 3.6, the lipophilic propranolol can easily cross the blood–brain barrier (BBB) [6]. Because the BBB of infants is not fully developed and oral propranolol was administered for a relatively long period in children with IHs, propranolol may have potential effects on infants [5, 21, 22].…”

Section: Discussionmentioning

confidence: 99%

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Yang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Objective To analyse the short-term adverse effects (AEs) of propranolol in the treatment of infantile hemangiomas (IHs) and their relevant factors, as well as the relationship between child growth and propranolol. Methods A total of 506 patients with confirmed or suspected IHs were enrolled, and a total of 439 cases were included in the study. Short-term AEs were analysed using single-factor analysis and binary logistic regression. Out of 439 patients, 292 were enrolled to examine the effect of propranolol on 2-year-olds' height and body weight (BW), by comparison with reference range and among groups. Spearman rank correlation analysis was used to determine the relationship between BW, height, and duration of propranolol treatment. Results Among 439 patients, 70 (16.0%) experienced AEs. Among them, 48 had gastrointestinal (GI) symptoms, 23 had central nervous system (CNS) symptoms, 8 had both symptoms above, and 7 had other symptoms. Most of the AEs occurred on the starting day (day 0), and 6 children's AEs were transient. Starting age of no older than 3 months led to more CNS symptoms, and starting age of older than 3 months was a protective factor against CNS symptoms, with an OR value of 0.303 (0.117–0.783). Height and BW of 292 two-year-old children were no less than the reference levels, although those of 3 females and 1 male were less than the average −2 standard deviation (−2SD). The height and BW of the children at the age of two was not related to the length of time of propranolol treatment. Conclusion Oral propranolol has a good tolerance in the treatment of IHs. Oral propranolol exerts more adverse effects on the CNS of lower age children, and it has exhibited no effect on the growth of two-year-old children.

show abstract

Section: Discussionmentioning

confidence: 99%

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Yang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The clinical outcomes included 17 (53.1%) excellent responses, 8 (25.0%) good responses and 7 (21.9%) moderate responses, while recurrence was observed in 3 (9.4%) patients. Kagami and Katori 14 reported five Japanese patients treated with 2 mg/kg per day of oral propranolol for IH beyond the proliferative phase and compared with three untreated patients. After the oral propranolol treatment for 25 weeks, all treated patients exhibited earlier color fading than untreated patients.…”

Section: Discussionmentioning

confidence: 99%

Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study

Kridin

Pam

Bergman

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase. Evaluation of the effectiveness of oral propranolol is less established when it is administered in late infancy following the proliferative phase. We aimed to assess the clinical outcomes of pediatric patients managed by oral propranolol beyond the proliferative phase of IH. A retrospective cohort study in a tertiary health care referral center was conducted to track all patients with IH receiving systemic propranolol following the proliferative phase. Twenty‐eight eligible patients were managed by 2 to 3 mg/kg per day of oral propranolol for IH beyond the proliferative phase, defined at 9 months of age. The mean age at the initiation of propranolol was estimated at 11.25 (SD 2.24) months. All eligible patients experienced some degree of clinical resolution, with the average improvement rate being estimated at 77.1% (SD 16.1). Comparable results were achieved among patients who were placed on propranolol at an age older than 12 months and those managed between the age of 9 and 12 months. No serious adverse events were observed during the follow‐up duration. In conclusion, oral propranolol is a safe and effective treatment for patients with IH initiating this agent beyond the proliferative phase.

show abstract

Improvement of Approaches to Treatment of Children With Superficial Infantile Hemangiomas of the Head and Neck Using High-Energy Lasers

Diomidov

Mandra

Chernyad'ev³

et al. 2020

Actual Problems in Dentistry

View full text Add to dashboard Cite

Background. Hemangiomas of the skin and mucous membranes, which belong to the group of vascular abnormalities, make up about 50% among other soft tissue tumors in children. Laser coagulation is one of the treatment methods that can provide both a radical removal of superficial hemangiomas and leaving an imperceptible trace. The goal is to increase the effectiveness of treatment of children with superficial infant hemangiomas of the head and neck by substantiating the differentiated selection of a high-energy laser. Methodology. A total of 512 children were included in the study. In accordance with the tasks of the study, the total body of material was divided into four parts: evaluation of the long-term results of the treatment of infant hemangiomas; a comparative study of the effectiveness of two laser systems in the treatment of infantile hemangiomas with varying degrees of elevation over the surrounding skin; assessment of the aesthetic efficiency of using laser technologies against the background of the modernization of the cooling method in the treatment of infantile hemangiomas of the face and neck in children; the study of the social effectiveness of the protocol for choosing a method of treatment of infantile hemangiomas of the head and neck in children. Results. The obtained statistically significant difference in changes on all scales between the two groups mathematically confirmed that the modernized approach makes it possible to obtain higher social effectiveness of the treatment, apparently due to the greater aesthetics of the remaining scars after treatment. Conclusions. A pronounced difference was found in the response of hemangiomas to various types of lasers, the combination of laser-coagulation with constant water cooling has a greater aesthetic effectiveness than the use of periodic ice applications, the social effectiveness of the approach using the protocol for choosing treatment tactics is higher than with standard approaches.

show abstract

Oral propranolol for infantile hemangiomas beyond the proliferative phase

Cited by 4 publications

References 13 publications

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two

Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study

Improvement of Approaches to Treatment of Children With Superficial Infantile Hemangiomas of the Head and Neck Using High-Energy Lasers

Contact Info

Product

Resources

About